Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2023-12-01 00:00:00 ET · period of report 2023-11-29 · accession 0001839516-23-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-01 | 2023-11-30 | TARS | Whitfield Dianne C. | CHRO | S - Sale+OE | $16.31 | -8,355 | 26.8K | -24% | -$136.3K |
| D | 2023-12-01 | 2023-11-29 | TARS | Whitfield Dianne C. | CHRO | M - OptEx | $0.00 | +23.9K | 35.1K | +213% | $0 |
| D | 2023-12-01 | 2023-11-29 | TARS | Whitfield Dianne C. | CHRO | M - OptEx | $0.00 | -23.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-30 | S | D | 8,355 | $16.31 | 26,784 | D | — | — | (F2) The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| 2 | Common | Common Stock | 2023-11-29 | M | A | 23,920 | $0.00 | 35,139 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2023-11-29 | M | D | 23,920 | $0.00 | 0 | D | — · — to — | 23,920 Common Stock | (F3) RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 30% of the RSUs vested on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. |